Efficacy and Safety of Adjunctive Zonisamide in Myoclonic Seizures Associated With Idiopathic Generalised Epilepsy
- Registration Number
- NCT00693017
- Lead Sponsor
- Eisai Limited
- Brief Summary
This study is intended to provide evidence that zonisamide is safe and effective in the treatment of myoclonic seizures. The total planned trial duration will be 6.5 months. After that, subjects who have completed the study will be eligible to enroll in an open-label extension study until zonisamide is marketed for this indication or further development in this indication stops. This extension study will be described in a separate protocol (E2090-E044-318).
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- All
- Target Recruitment
- 10
- Subject is male or female and aged 12-65 years.
- Subject has at least eight days with at least one myoclonic seizure over the two months Baseline Period. Myoclonic seizures must occur in the context of IGE and may be accompanied by other primary generalized seizures, provided these are also consistent with a diagnosis of Idiopathic Generalized Epilepsy (IGE).
- Subject (or parent/caregiver, for subjects below the age of consent) is willing to sign an informed consent form. Subjects below the age of consent in their country, must where appropriate be willing to give informed (written or verbal) assent. Subjects from the age specified in local regulations will be required to sign an appropriate informed consent form.
- Subject is taking a stable regimen of one or two other AEDs for at least two weeks prior to Visit 1 (start of the Baseline Period).
- Subject has a clinical diagnosis of any type of idiopathic generalised epilepsy (IGE) which has myoclonic seizures (and which may be accompanied by other generalised seizure types), according to the International League Against Epilepsy (ILAE) Classification of Epileptic Seizures (1981) and the ILAE Classification of Epilepsies and Epileptic Syndromes (1989). Diagnosis should have been established by clinical history, electroencephalogram (EEG) and computed tomography/magnetic resonance imaging (CT/MRI) of the brain consistent with idiopathic generalised epilepsy. A CT/MRI scan should have been performed within five years of the screening visit or, if not available from this period, should be performed in the Baseline Period.
- EEG should have been performed within one year of the screening visit or, if not available from this period, should be performed in the Baseline Period.
- Female subjects are pre-menarchal, or if of childbearing potential, are not pregnant or lactating, or are post-menopausal.
- Female subjects of childbearing potential ≥ 18 years must abide by one of the following medically acceptable contraceptive measures: oral contraception pill, contraceptive injections, implants or patches, intrauterine device in place for at least three months or vasectomised partner or abstinence throughout the study. Subjects <18 years and of childbearing potential must be either abstinent or willing to use one of the medically appropriate forms of contraception for the duration of the study.
- Subject has progressive or focal neurological disease (as determined by preexisting brain imaging such as CT or MRI performed maximally five years before the screening visit), or clinically significant organic disease.
- Subject has a history of, or results of clinical investigations (including EEG data) that are suggestive of, partial seizures as defined by the ILAE, including generalised tonic clonic seizures which are suspected to be secondarily generalised.
- Subjects with cryptogenic or symptomatic generalised epilepsy.
- Subjects with psychogenic seizures.
- Subject has a history of convulsive status epilepticus within a year of screening while complying with AEDs.
- Subject has a history of renal calculi or renal insufficiency (above the upper normal limits of creatinine).
- Subject has a known diagnosis of human immunodeficiency virus (HIV) or hepatitis B or C.
- Subject has a predisposing condition that might interfere with absorption, distribution, or excretion of zonisamide.
- Subject has a history of sensitivity to sulfonamide drugs or to zonisamide or any of its excipients.
- Subject has a recent history of excessive alcohol use or drug abuse.
- Subject has a history of suicide attempt in the five years before the screening visit.
- Subject has abnormal screening laboratory values that are clinically significant.
- Subject has a history of demonstrated non-compliance with treatment, or the subject or parent/caregiver can be reasonably expected not to be compliant with study procedures or to complete the study.
- Subject has participated in a study of an investigational drug or device within 30 days prior to screening.
- Subject has received previous treatment with zonisamide.
- Subject is treated with ketogenic diet or vagus nerve stimulator.
- Subject has a history of necessary treatment with rescue benzodiazepines which is foreseen to continue during the study. Rescue benzodiazepines will not be allowed in this study (stable dosing with a benzodiazepine as (one of the) baseline anti-epileptic drug(s) is allowed).
- Concomitant use of acetazolamide, carbonic anhydrase inhibitors such as topiramate and drugs with anticholinergic activity.
- Current psychosis or moderate to severe depression, or use of anti-psychotic drugs, MAOIs, tricyclic antidepressants, benzodiazepine or barbiturate treatment for disorders other than epilepsy, and stimulants (amphetamine derivatives) within 28 days before the screening visit.
- Concomitant use of felbamate or use of felbamate within two months prior to Visit 1.
- Subject is unable to swallow capsules.
- Subject is not in general good health as determined by medical history, physical exam and screening laboratory results.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Placebo Placebo - Zonisamide Zonisamide -
- Primary Outcome Measures
Name Time Method Number of Participants Considered Responders as Assessed During the Maintenance Period Baseline (Week -8 to Week 0) and Maintenance Period (Week 4 to Week 16) The number of participants who were considered responders during the 12 week Maintenance Period (Week 4 to Week 16). A responder was defined as a participant with a decrease \>= 50% from baseline in the number of days with myoclonic seizures per 28 days (i.e. 28-day myoclonic seizure frequency in Period from Week 4 to the Week 16 visit compared to Week -8 to randomization at Week 0 \[Screening/ Baseline Period\]). Occurrence of seizures was documented in a seizure diary. The diary was dispensed at the Screening Visit and maintained by the participant (parent/caregiver) and reviewed at each following visit. The diary was completed daily. All seizures except myoclonic seizures were counted individually in the the diary. Due to early termination of the study by the Sponsor, no formal analyses were conducted.
- Secondary Outcome Measures
Name Time Method Percentage Change From Baseline in the Monthly Number of Days With Myoclonic Seizures Baseline and up to 16 weeks Percentage Change from Baseline in the monthly number of days with myoclonic seizures was assessed both for the Maintenance Period alone (Week 4 to Week 16) and for the entire double-blind treatment period (Week 0 to Week 16). Due to early termination of the study by the Sponsor, no formal analyses were conducted.
Trial Locations
- Locations (71)
Strategic Health Evaluators Pty Ltd
🇦🇺Chatswood, New South Wales, Australia
The Prince of Wales Hospital
🇦🇺Randwick, New South Wales, Australia
Vas County Markusovszky Hospital
🇭🇺Szombathely, Hungary
Spitalul Clinic de Psihiatrie "Prof. Dr. Alexandru Obregia"
🇷🇴Bucharest, Romania
Tsentr Psihosomatychnoyi Patologiyi Dnipropetrovskoyi oblasnoyi klinichnoyi likarni imeni Mechnikova
🇺🇦Dnipropetrovsk, Ukraine
Derzhavna Ustanova Institut Nevrologiy
🇺🇦Kharkiv, Ukraine
Clinical Center of NIS
🇷🇸Nis, Serbia
Nemocnice Na Homolce
🇨🇿Praha 5, Czech Republic
Tartu University Hospital
🇪🇪Tartu, Estonia
Oulu University Central Hospital
🇫🇮Oulu, Finland
National Institute of Psychiatry and Neurology
🇭🇺Budapest, Hungary
CH Split
🇭🇷Split, HR, Croatia
West-Tallinn Central Hospital
🇪🇪Tallinn, Estonia
Veszprem County Csolnoky F. Hospital
🇭🇺Veszprem, Hungary
Neuromeda
🇱🇹Kaunas, Lithuania
Centrum Neurologii Klinicznej
🇵🇱Krakow, Poland
GOU VPO Krasnoyarskaya State Medical Academy of Roszdrav
🇷🇺Krasnoyarsk, Russian Federation
GOU VPO Smolensk State Medical Academy of Roszdrav
🇷🇺Smolensk, Russian Federation
GOU VPO St. Petersburg State Medical University
🇷🇺St. Petersburg, Russian Federation
Yaroslavskaya State Medical Academy
🇷🇺Yaroslavl, Russian Federation
Clinical Center of Serbia
🇷🇸Belgrade, Serbia
Odesskyy Derzhavnyy Medychnyy Universitet
🇺🇦Odesa, Ukraine
FGU Moscow Research Institute of Psychiatry of Roszdrav
🇷🇺Moscow, Russian Federation
GOU VPO Russian State Medical University of Roszdrav
🇷🇺Moscow, Russian Federation
Neurodiagnostica AP OY
🇪🇪Tallinn, Estonia
Bekes County Pandy Kalman Hospital
🇭🇺Gyula, Hungary
Kaunas Medical University Hospital
🇱🇹Kaunas, Lithuania
University Medical Center Zvezdara
🇷🇸Belgrade, Serbia
Clinical center Kragujevac
🇷🇸Kragujevac, Serbia
Vinnitskyy Natsionalnyy Medychnyy Universitet
🇺🇦Vinnitsa, Ukraine
CH Sestre Milosrdnice University Hospita
🇭🇷Zagreb, HR, Croatia
Spitalul Universitar de Urgenta Bucuresti
🇷🇴Bucharest, Romania
Spitalul Clinic de Urgenta "Sfanta Treime"
🇷🇴Lasi, Romania
Spitalul Clinic Judetean de Urgenta Tg Mures
🇷🇴Tg Mures, Romania
Lvivskyiy oblasnyi Protyepileptuchnyy tsentr
🇺🇦Lviv, Ukraine
GOU VPO Moscow State University of Medicine and Dentistry of Roszdra
🇷🇺Moscow, Russian Federation
Fakultni nemocnice s poliklinikou Ostrava
🇨🇿Ostrava, Czech Republic
Centrum neurologicke pece
🇨🇿Rychnov nad Kneznou, Czech Republic
Vilnius University Hospital Santariskiu klinikos
🇱🇹Vilnius, Lithuania
Niepubliczny ZOZ Kendron
🇵🇱Bialystok, Poland
Wojewozki Szpital Specjalistyczny im. M. Kopernika
🇵🇱Gdansk, Poland
Specjalistyczny Szpital Wieloprofilowy
🇵🇱Katowice, Poland
Uniwersytet Medyczny
🇵🇱Poznan, Poland
Centrul Medical Sana
🇷🇴Bucharest, Romania
Spitalul Clinic Judetean de Urgenta "Sf Spiridon" Iasi
🇷🇴Lasi, Romania
GU St. Petersburg Research Institute of Psychoneurology Bekhtereva of Roszdrav
🇷🇺St. Petersburg, Russian Federation
St. Petersburg State Medical Pediatric Academy
🇷🇺St. Petersburg, Russian Federation
The Royal Melbourne Hospital
🇦🇺Melbourne, Victoria, Australia
Spitalul Clinic Judetean de Urgenta Cluj
🇷🇴Cluj-Napoca, Romania
GOU VPO Novosibirsk State Medical University of Roszdrav
🇷🇺Novosibirsk, Russian Federation
Kyiv City Psychiatric Hospital #2, Poliklinichne Viddilenya
🇺🇦Kyiv, Ukraine
Miska Klinichna psihonevrologichna
🇺🇦Kyiv, Ukraine
Szent Istvan Hospital
🇭🇺Budapest, Hungary
Orszagos Idegsebeszeti Tudomanyos Intezet
🇭🇺Budapest, Hungary
Austin Health
🇦🇺Heidelburg, Victoria, Australia
UHC Zagreb
🇭🇷Zagreb, HR, Croatia
Kuopio Epilepsy Center
🇫🇮Kuopio, Finland
Heim Pal Hospital
🇭🇺Budapest, Hungary
Szpital im. M. Kopernika
🇵🇱Lodz, Poland
Neurologicke oddeleni
🇨🇿Kralove, Czech Republic
Neurochirurgische Klinik der Universitat Freiburg
🇩🇪Freiburg, Germany
Fakultni nemocnice Plzen
🇨🇿Plzen, Czech Republic
Private Neurologi Office
🇨🇿Kromeriz, Czech Republic
Fakultni nemocnice Olomouc
🇨🇿Olomouc, Czech Republic
Interdisziplinares Epilepsiezentrum am Klinikum der Philipps-Universitat Marburg
🇩🇪Marburg, Germany
Institut fur Diagnostik der Epilepsien (IDE) gGmbH Epilepsie-Zentrum Berlin- Brandenburg.
🇩🇪Berlin, Germany
Neurologische Gemeinschaftspraxis
🇩🇪Munchen, Germany
Universitatsklinikum Ulm
🇩🇪Ulm, Germany
Bacs-Kiskun County ONK Hospital
🇭🇺Kecskemet, Hungary
GUZ of Moscow City Clinical Hospital #1 n.a. N.I.Pirogov
🇷🇺Moscow, Russian Federation
Bethesda Hospital for Children
🇭🇺Budapest, Hungary